In line with this, recent reports showed that targeting the PI3K/AKT/mTOR pathway resulted in a compensatory increase in the RAS/RAF/MEK/MAPK pathway in primary prostate tumour samples [44], indicating strong crosstalk between those pathways as postulated earlier [45]. The gene discussed is AKT1; the disease is prostate neoplasm.